Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats.
The 5-hydroxytryptamine (5-HT)-induced late depressor response in rats is mainly mediated by vascular 5-HT7 receptors. The present study was devoted to determining the systemic and regional haemodynamic changes during this response, with particular emphasis on localising vascular beds that may contribute to the increase in total systemic vascular conductance. In vagosympathectomised, pentobarbital-anaesthetised rats pretreated with the 5-HT2 receptor antagonist ritanserin (50 microg kg(-1), i.v.), 5-HT (1, 3 and 10 ug kg(-1) min(-1) during 10 min; i.v.) produced a dose-dependent decrease in mean arterial blood pressure by up to 46+/-3%. This decrease was accompanied by increases in systemic vascular conductance by up to 83+/-15%; cardiac output was unaffected. 5-HT increased regional vascular conductance in skeletal muscle, carcass, mesentery/pancreas and adrenals by up to 740+/-14%, 117+/-18%, 135+/-26% and 88+/-22%, respectively, but decreased 'lung' (mainly arteriovenous anastomotic) conductance by up to 81+/-2%. Pretreatment with R(+)lisuride (100 microg kg(-1), i.v.) abolished all 5-HT-induced systemic and regional haemodynamic effects. In contrast, i.v. pretreatment with S(-)lisuride (100 microg kg(-1)) or GR127935 (300 microg kg(-1)) did not affect the 5-HT-induced systemic haemodynamic changes. The above results suggest that hypotension induced via 5-HT7 receptor activation was exclusively caused by vasodilatation of the systemic vasculature, confined to skeletal muscle, carcass, mesentery/pancreas and adrenal vascular beds. Furthermore, this study shows that blockade of vasorelaxant 5-HT7 receptors by lisuride is stereoselective.
De Vries
P
P
Department of Pharmacology, Cardiovascular Research Institute "COEUR", Erasmus University Medical Centre Rotterdam "EMCR", The Netherlands.
De Visser
P A
PA
Heiligers
J P
JP
Villalón
C M
CM
Saxena
P R
PR
D000311:Adrenal Glands / Q000098:blood supply; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D002302:Cardiac Output / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D007668:Kidney / Q000098:blood supply; D008090:Lisuride / Q000737:chemistry / Q000494:pharmacology; D008168:Lung / Q000098:blood supply; D008297:Male; D018482:Muscle, Skeletal / Q000098:blood supply; D010069:Oxadiazoles / Q000494:pharmacology; D010179:Pancreas / Q000098:blood supply; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011985:Receptors, Serotonin / Q000502:physiology*; D012016:Reference Values; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013237:Stereoisomerism; D013318:Stroke Volume / Q000187:drug effects; D018924:Vascular Capacitance / Q000187:drug effects
D010069:Oxadiazoles; D010879:Piperazines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C104425:serotonin 7 receptor; C090701:GR 127935; D012701:Serotonin; D008090:Lisuride